Patents by Inventor Christine Günther

Christine Günther has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220033779
    Abstract: A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter/enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and/or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 3, 2022
    Inventors: Christine Günther, Manfred Stangl, Felix Hermann
  • Publication number: 20200289577
    Abstract: A method of protecting a vascular endothelium from CD8+ cytotoxic T-lymphocyte mediated cytotoxic reactions in a subject who is about to receive or who has received an allogenic transplant and is at risk of developing or is afflicted with transplant-related complications, the method including administering to the subject human CD34-negative progenitor cells.
    Type: Application
    Filed: March 30, 2020
    Publication date: September 17, 2020
    Inventors: Günther EISSNER, Christine GUENTHER, Ralf HUSS
  • Publication number: 20200282078
    Abstract: A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response, and said subject does not have an alpha1-antitrypsin (AAT) deficiency, wherein the method includes administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells include an exogenous nucleic acid including (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: February 25, 2020
    Publication date: September 10, 2020
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • Publication number: 20200268802
    Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.
    Type: Application
    Filed: January 28, 2020
    Publication date: August 27, 2020
    Inventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
  • Publication number: 20190030152
    Abstract: A tumor or a malignant disease can be treated by the combined administration of mesenchymal stem cells (MSCs) with an anti-tumor immunotherapy. The MSCs need not be genetically modified, and do not include exogenous nucleic acids that encode immune response-stimulating cytokines. The anti-tumor immunotherapy can be a cellular immunotherapy, such as administration of chimeric antigen receptor (CAR) T cells, in which the T cell receptor binds specifically to a tumor-associated antigen.
    Type: Application
    Filed: March 31, 2017
    Publication date: January 31, 2019
    Inventors: Felix Hermann, Christine Günther, Ulf Geumann
  • Publication number: 20180037868
    Abstract: A genetically modified mesenchymal stem cell (MSC) includes an exogenous nucleic acid that includes a Klotho encoding region operably linked to a promoter or promoter/enhancer combination. The MSCs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as Alzheimer's disease (AD), Multiple sclerosis (MS), Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and Schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 8, 2018
    Inventors: Christine Günther, Manfred Stangl, Felix Hermann
  • Publication number: 20180000969
    Abstract: Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • Publication number: 20170239297
    Abstract: A genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumors, the MSC including one or more exogenous nucleic acid molecule(s), wherein the exogenous nucleic acid molecule(s) include a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter/enhancer combination. The invention encompasses the use of the cells in modulating the tumor microenvironment in order to attract immune effector cells and facilitate their activation and/or adoption of a memory phenotype.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 24, 2017
    Inventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
  • Publication number: 20160008401
    Abstract: The present invention provides human CD34-negative progenitor cells for the use in protecting the vascular endothelium from immunologically mediated cytotoxic reactions of a subject at risk of, or afflicted with, vascular inflammatory disease. Also provided are a method for producing the human CD34-negative progenitor cells and a method for determining the ability of CD34-negative progenitor cells to protect the vascular endothelium from immunologically mediated cytotoxic reactions.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Inventors: Günther Eissner, Christine Guenther, Ralf Huss
  • Publication number: 20140087459
    Abstract: This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 ?m in diameter; (b) a human fresh frozen plasma (FFP) filtrate free of solid matter greater than 0.22 ?m in diameter; (c) heparin; (d) L-glutamine; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the cell growth medium permits the expansion of human CD34? stem cells and wherein the resulting expanded CD34? stem cells retain the ability to differentiate. This invention also provides related cell growth medium supplements, a sterile human platelet lysate and human fresh frozen plasma (FFP) filtrate, kits, CD34? stem cell-containing compositions, and related production and cell expansion methods.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 27, 2014
    Applicant: Apceth GmbH & Co. KG
    Inventors: Elena Meurer, Christine GÜNTHER
  • Patent number: 8557578
    Abstract: This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 ?m in diameter, wherein the lysate constitutes from 2% to 15% of the total volume of the cell growth medium; (b) a human fresh frozen plasma (FFP) filtrate free of solid matter greater than 0.22 ?m in diameter, wherein the FFP filtrate constitutes from 1% to 10% of the total volume of the cell growth medium; (c) heparin at a concentration of from 0 U/ml to 10 U/ml of the cell growth medium; (d) L-glutamine at a concentration of from 0.5 mM to 10 mM; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the serum-free, low glucose medium constitutes from 75% to 97% of the total volume of the cell growth medium, and may contain the L-glutamine of part (d); wherein the cell growth medium permits the expansion of human CD34? stem cells and wherein the resulting expanded CD34? stem cells retain the ability to differentiate.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: October 15, 2013
    Assignee: Apceth GmbH & Co. KG
    Inventors: Elena Aseeva, Christine Günther
  • Publication number: 20110183414
    Abstract: This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 ?m in diameter, wherein the lysate constitutes from 2% to 15% of the total volume of the cell growth medium; (b) a human fresh frozen plasma (FFP) filtrate free of solid matter greater than 0.22 ?m in diameter, wherein the FFP filtrate constitutes from 1% to 10% of the total volume of the cell growth medium; (c) heparin at a concentration of from 0 U/ml to 10 U/ml of the cell growth medium; (d) L-glutamine at a concentration of from 0.5 mM to 10 mM; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the serum-free, low glucose medium constitutes from 75% to 97% of the total volume of the cell growth medium, and may contain the L-glutamine of part (d); wherein the cell growth medium permits the expansion of human CD34? stem cells and wherein the resulting expanded CD34? stem cells retain the ability to differentiate.
    Type: Application
    Filed: December 22, 2010
    Publication date: July 28, 2011
    Applicant: Apceth GmbH & Co. KG
    Inventors: Elena Aseeva, Christine Günther